🔗 Share this article

Given that the US proceeds with sweeping adjustments to its vaccination schedules, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by casting doubt on Covid vaccinations in the pandemic and has concentrated on potential fatalities after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Program

Agency leaders were set to announce sweeping changes to the childhood vaccination calendar in December, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US at odds with a large portion of the world with little proof for public health gain. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

The new acting director has often pushed for halting certain pediatric immunization guidelines in the US in order to be more like Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on vaccines – traditionally the purview of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Concerns Over Expertise

Høeg has no apparent background in pharmaceutical research, approval processes or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who headed CBER have had.”

CDER has an immense workload at the FDA, she pointed out.

“Everybody just zeroes in on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and more, and each of these have to be supervised,” Dr. Woodcock said. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial leadership aspect to the job, which oversees more than 5,000 staff members. “It’s a massive management job, if you execute it properly,” Woodcock added.

Official Statement and Controversial Programs

In response to concerns about Høeg’s qualifications and whether this selection represents more teamwork among agency officials on vaccines, a press secretary stated that the “inquiries are based on flawed assumptions”.

“Her resume matches the responsibilities of her role,” the spokesperson explained, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the agency head's new expedited review system, a disputed rapid drug-approval program that allegedly troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Howard questioned. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of pharmaceuticals, except for immunizations.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, past, some experts observe. She released a research paper using unverified crowd-sourced reports to estimate the incidence of heart inflammation after COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are riskier than they are.

Included in her “wish list” for the current administration included revising regulations for new vaccines and discontinuing “optional” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She’s an complete true believer who commences with her conclusions and works backwards to retrofit the evidence in a extremely deceptive, dishonest way,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|